Saturday 10 October 2026 Export all ABBV data to Excel Powerpack

AbbVie Inc.

ABBV Healthcare Drug Manufacturers General

AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 290.4%, free cash flow fell 36.2% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.

276.47 4.05 +1.49%
Market cap
$481.4B
P/E
78.1×
Fwd P/E
27.8×
Dividend yield
3.10%
F-score
8/9
Altman Z
2.31
Beneish M
−2.86
Dividend safety
44/100

AbbVie Inc. (ABBV) EV/FCF

Alert me on EV/FCF

As of 9 October 2026, AbbVie Inc. (ABBV) trades at a EV/FCF of 30.4×. Over the past ten years it has ranged from 9.6× (March 2020) to 39.0× (January 2015); the current reading is higher than 96% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 26.2× 24.19%
FY2024 21.1× 41.32%
FY2023 14.9× 5.89%
FY2022 14.1× 1.07%
FY2021 13.9× (8.65%)
FY2020 15.3× 23.40%
FY2019 12.4× (9.28%)
FY2018 13.6× (30.38%)
FY2017 19.6× (2.41%)
FY2016 20.1× 17.54%

Quarterly newest first

Period EV/FCF Change
Jun 2026 28.0× 24.64%
Mar 2026 22.4× (14.28%)
Dec 2025 26.2× 9.04%
Sep 2025 24.0× 11.67%
42 more quarters

Against its own ten years

Low 9.6× High 39.0×
Ten-year median 16.6×
Current reading's percentile 100

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on ABBV